Maury Raycroft
Stock Analyst at Jefferies
(0.73)
# 3,995
Out of 5,005 analysts
49
Total ratings
26.32%
Success rate
-10.86%
Average return
Main Sectors:
Top Industries:
Stocks Rated by Maury Raycroft
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| KOD Kodiak Sciences | Initiates: Buy | $15 | $15.06 | -0.40% | 1 | Sep 22, 2025 | |
| ALNY Alnylam Pharmaceuticals | Maintains: Buy | $328 → $384 | $456.35 | -15.85% | 2 | Jul 7, 2025 | |
| CRDF Cardiff Oncology | Initiates: Hold | $3.5 | $2.19 | +59.82% | 1 | Jun 24, 2025 | |
| CRBP Corbus Pharmaceuticals Holdings | Maintains: Buy | $70 → $53 | $14.83 | +257.38% | 2 | Mar 11, 2025 | |
| CMPX Compass Therapeutics | Maintains: Buy | $7 → $8 | $3.70 | +116.22% | 2 | Feb 10, 2025 | |
| SGMO Sangamo Therapeutics | Maintains: Buy | $7 → $3 | $0.68 | +339.30% | 1 | Dec 31, 2024 | |
| MREO Mereo BioPharma Group | Initiates: Buy | $7 | $2.04 | +243.14% | 1 | Dec 6, 2024 | |
| ERAS Erasca | Initiates: Buy | $6 | $2.42 | +147.93% | 1 | Nov 18, 2024 | |
| TNGX Tango Therapeutics | Initiates: Buy | $19 | $7.76 | +144.85% | 1 | Jul 17, 2024 | |
| PRME Prime Medicine | Assumes: Buy | $23 → $15 | $6.32 | +137.34% | 1 | May 7, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $22 → $39 | $34.94 | +11.62% | 2 | Mar 22, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $6 | $0.73 | +722.93% | 1 | Mar 13, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $23 | $2.65 | +767.92% | 1 | Mar 5, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $195 | $10.40 | +1,775.00% | 1 | Feb 8, 2024 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $11 | $7.15 | +53.85% | 8 | Aug 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $32 → $6 | $30.14 | -80.09% | 2 | Jan 4, 2023 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $92 → $75 | $36.12 | +107.64% | 5 | Nov 29, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $11 | $9.10 | +20.88% | 1 | Sep 12, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $31 → $27 | $13.66 | +97.66% | 3 | Mar 8, 2022 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Downgrades: Hold | $38 → $5 | $1.75 | +185.71% | 2 | Dec 2, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $48 | $50.51 | -4.97% | 1 | Sep 7, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $36 | $11.39 | +216.07% | 1 | Jun 1, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $105 | $5.90 | +1,679.66% | 1 | May 27, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Upgrades: Buy | $172 | $67.74 | +153.91% | 2 | Apr 21, 2021 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $47 | $3.89 | +1,108.23% | 1 | Feb 24, 2020 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Initiates: Buy | $230 | $3.92 | +5,767.35% | 1 | Jul 16, 2018 | |
| XXXX XXXXXXXXXXXXXXXX Upgrade | Maintains: Buy | $36 → $42 | $19.96 | +110.42% | 3 | Nov 1, 2017 |
Kodiak Sciences
Sep 22, 2025
Initiates: Buy
Price Target: $15
Current: $15.06
Upside: -0.40%
Alnylam Pharmaceuticals
Jul 7, 2025
Maintains: Buy
Price Target: $328 → $384
Current: $456.35
Upside: -15.85%
Cardiff Oncology
Jun 24, 2025
Initiates: Hold
Price Target: $3.5
Current: $2.19
Upside: +59.82%
Corbus Pharmaceuticals Holdings
Mar 11, 2025
Maintains: Buy
Price Target: $70 → $53
Current: $14.83
Upside: +257.38%
Compass Therapeutics
Feb 10, 2025
Maintains: Buy
Price Target: $7 → $8
Current: $3.70
Upside: +116.22%
Sangamo Therapeutics
Dec 31, 2024
Maintains: Buy
Price Target: $7 → $3
Current: $0.68
Upside: +339.30%
Mereo BioPharma Group
Dec 6, 2024
Initiates: Buy
Price Target: $7
Current: $2.04
Upside: +243.14%
Erasca
Nov 18, 2024
Initiates: Buy
Price Target: $6
Current: $2.42
Upside: +147.93%
Tango Therapeutics
Jul 17, 2024
Initiates: Buy
Price Target: $19
Current: $7.76
Upside: +144.85%
Prime Medicine
May 7, 2024
Assumes: Buy
Price Target: $23 → $15
Current: $6.32
Upside: +137.34%
Mar 22, 2024
Maintains: Buy
Price Target: $22 → $39
Current: $34.94
Upside: +11.62%
Mar 13, 2024
Initiates: Buy
Price Target: $6
Current: $0.73
Upside: +722.93%
Mar 5, 2024
Initiates: Buy
Price Target: $23
Current: $2.65
Upside: +767.92%
Feb 8, 2024
Initiates: Buy
Price Target: $195
Current: $10.40
Upside: +1,775.00%
Aug 4, 2023
Upgrades: Buy
Price Target: $11
Current: $7.15
Upside: +53.85%
Jan 4, 2023
Downgrades: Hold
Price Target: $32 → $6
Current: $30.14
Upside: -80.09%
Nov 29, 2022
Maintains: Buy
Price Target: $92 → $75
Current: $36.12
Upside: +107.64%
Sep 12, 2022
Initiates: Buy
Price Target: $11
Current: $9.10
Upside: +20.88%
Mar 8, 2022
Upgrades: Buy
Price Target: $31 → $27
Current: $13.66
Upside: +97.66%
Dec 2, 2021
Downgrades: Hold
Price Target: $38 → $5
Current: $1.75
Upside: +185.71%
Sep 7, 2021
Initiates: Buy
Price Target: $48
Current: $50.51
Upside: -4.97%
Jun 1, 2021
Initiates: Buy
Price Target: $36
Current: $11.39
Upside: +216.07%
May 27, 2021
Initiates: Buy
Price Target: $105
Current: $5.90
Upside: +1,679.66%
Apr 21, 2021
Upgrades: Buy
Price Target: $172
Current: $67.74
Upside: +153.91%
Feb 24, 2020
Initiates: Buy
Price Target: $47
Current: $3.89
Upside: +1,108.23%
Jul 16, 2018
Initiates: Buy
Price Target: $230
Current: $3.92
Upside: +5,767.35%
Nov 1, 2017
Maintains: Buy
Price Target: $36 → $42
Current: $19.96
Upside: +110.42%